Molecular Modeling of ALK L1198F and/or G1202R Mutations to Determine Differential Crizotinib Sensitivity

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that has been recognized as a therapeutic target for EML4-ALK fusion-positive nonsmall cell lung cancer (NSCLC) treatment using type I kinase inhibitors such as crizotinib to take over the ATP binding site. According to Shaw’s measuremen...

Descripción completa

Detalles Bibliográficos
Autores principales: Chuang, Yu-Chung, Huang, Bo-Yen, Chang, Hsin-Wen, Yang, Chia-Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684801/
https://www.ncbi.nlm.nih.gov/pubmed/31388026
http://dx.doi.org/10.1038/s41598-019-46825-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684801/
https://www.ncbi.nlm.nih.gov/pubmed/31388026
http://dx.doi.org/10.1038/s41598-019-46825-1

Ejemplares similares